These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 35881170)

  • 21. Treatment of Alzheimer's disease: current status and new perspectives.
    Scarpini E; Scheltens P; Feldman H
    Lancet Neurol; 2003 Sep; 2(9):539-47. PubMed ID: 12941576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
    Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
    Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology.
    O'Brien JT; Holmes C; Jones M; Jones R; Livingston G; McKeith I; Mittler P; Passmore P; Ritchie C; Robinson L; Sampson EL; Taylor JP; Thomas A; Burns A
    J Psychopharmacol; 2017 Feb; 31(2):147-168. PubMed ID: 28103749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective pharmacological management of Alzheimer's disease.
    Atri A
    Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
    Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
    Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholinesterase inhibitors and non-steroidal anti-inflammatory drugs as Alzheimer's disease therapies: an updated umbrella review of systematic reviews and meta-analyses.
    Wang CH; Wang LS; Zhu N
    Eur Rev Med Pharmacol Sci; 2016 Nov; 20(22):4801-4817. PubMed ID: 27906438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.
    Liang J; Li J; Jia R; Wang Y; Wu R; Zhang H; Hang L; Xu Y
    Clin Interv Aging; 2018; 13():2061-2073. PubMed ID: 30425461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
    Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
    Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy.
    Delrieu J; Piau A; Caillaud C; Voisin T; Vellas B
    CNS Drugs; 2011 Mar; 25(3):213-26. PubMed ID: 21323393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current approaches to optimize treatment of dementia and Alzheimer's disease].
    Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):87-92. PubMed ID: 28635795
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
    Byun J; Lee DY; Jeong CW; Kim Y; Rhee HY; Moon KW; Heo J; Hong Y; Kim WJ; Nam SJ; Choi HS; Park JI; Chun IK; Bak SH; Lee K; Byeon GH; Kim KL; Kim JA; Park YJ; Kim JH; Lee EJ; Lee SA; Kwon SO; Park SW; Kasani PH; Kim JK; Kim Y; Kim S; Jang JW
    Sci Rep; 2022 Mar; 12(1):4451. PubMed ID: 35292697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
    Tricco AC; Ashoor HM; Soobiah C; Rios P; Veroniki AA; Hamid JS; Ivory JD; Khan PA; Yazdi F; Ghassemi M; Blondal E; Ho JM; Ng CH; Hemmelgarn B; Majumdar SR; Perrier L; Straus SE
    J Am Geriatr Soc; 2018 Jan; 66(1):170-178. PubMed ID: 29131306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
    Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
    BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Int J Technol Assess Health Care; 2002; 18(3):497-507. PubMed ID: 12391943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of cognitive enhancers for patients with mild cognitive impairment: a systematic review and meta-analysis.
    Tricco AC; Soobiah C; Berliner S; Ho JM; Ng CH; Ashoor HM; Chen MH; Hemmelgarn B; Straus SE
    CMAJ; 2013 Nov; 185(16):1393-401. PubMed ID: 24043661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacotherapy for Alzheimer's disease].
    Verhey FR
    Tijdschr Psychiatr; 2006; 48(1):17-26. PubMed ID: 16955982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
    Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M; Eap CB
    Clin Pharmacokinet; 2013 Apr; 52(4):225-41. PubMed ID: 23408070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.